EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands

Andrea Díaz-Tejedor iD, Javier Rodríguez-Ubreva, Laura Ciudad, Mauro Lorenzo-Mohamed iD, Marta González-Rodríguez, Bárbara Castellanos, Janet Sotolongo-Ravelo, Laura San-Segundo iD, Luis A Corchete iD, Lorena González-Méndez, Montserrat Martín-Sánchez, María-Victoria Mateos iD und 3 weitere

International Journal of Molecular Sciences · 26.04.2024 · 25 (9) · 4718

DOI: 10.3390/ijms25094718 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.04.2024. Verfasst von Andrea Díaz-Tejedor und 14 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Investigación del Cáncer-Instituto de Biología Molecular y Celular del Cáncer (CIC-IBMCC), Universidad de Salamanca, Consejo Superior de In…. Hauptthemen laut MEDLINE: ADP-ribosyl Cyclase 1, Antibodies, Monoclonal, Multiple Myeloma, NK Cell Lectin-Like Receptor Subfamily K. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mundipharma Research Limited; Purdue Pharma LP, Instituto de Salud Carlos III co-funded by European Union (ERDF, "A way to make Europe"), Instituto de Salud Carlos III co-funded by the European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma is a malignancy characterized by the accumulation of malignant plasma cells in bone marrow and the production of monoclonal immunoglobulin. A hallmark of cancer is the evasion of immune surveillance. Histone deacetylase inhibitors have been shown to promote the expression of silenced molecules and hold potential to increase the anti-MM efficacy of immunotherapy. The aim of the present work was to assess the potential effect of tinostamustine (EDO-S101), a first-in-class alkylating deacetylase inhibitor, in combination with daratumumab, an anti-CD38 monoclonal antibody (mAb), through different preclinical studies. Tinostamustine increases CD38 expression in myeloma cell lines, an effect that occurs in parallel with an increment in CD38 histone H3 acetylation levels. Also, the expression of MICA and MICB, ligands for the NK cell activating receptor NKG2D, augments after tinostamustine treatment in myeloma cell lines and primary myeloma cells. Pretreatment of myeloma cell lines with tinostamustine increased the sensitivity of these cells to daratumumab through its different cytotoxic mechanisms, and the combination of these two drugs showed a higher anti-myeloma effect than individual treatments in ex vivo cultures of myeloma patients’ samples. In vivo data confirmed that tinostamustine pretreatment followed by daratumumab administration significantly delayed tumor growth and improved the survival of mice compared to individual treatments. In summary, our results suggest that tinostamustine could be a potential candidate to improve the efficacy of anti-CD38 mAbs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ADP-ribosyl Cyclase 1Antibodies, MonoclonalMultiple MyelomaNK Cell Lectin-Like Receptor Subfamily KAnimalsHumansMiceCell Line, TumorDrug SynergismHistocompatibility Antigens Class IHistone Deacetylase InhibitorsMembrane GlycoproteinsUp-RegulationXenograft Model Antitumor AssaysBenzimidazoles

Stichwörter der Autor:innen

daratumumabimmunotherapymultiple myelomatinostamustine

Substanzen

ADP-ribosyl Cyclase 1Antibodies, MonoclonalCD38 protein, humandaratumumabHistocompatibility Antigens Class IHistone Deacetylase InhibitorsKLRK1 protein, humanMembrane GlycoproteinsMHC class I-related chain AMICB antigen

Autor:innen und Institutionen

  • Centro de Investigación del Cáncer-Instituto de Biología Molecular y Celular del Cáncer (CIC-IBMCC), Universidad de Salamanca, Consejo Superior de Investigaciones Científicas (CSIC), 37007 Salamanca, Spain.
  • Servicio de Hematología, Complejo Asistencial Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), 37007 Salamanca, Spain.
  • Epigenetics and Immune Disease Group, Josep Carreras Research Institute (IJC), 08916 Badalona, Spain.
  • Centro de Investigación Biomédica En Red de Cáncer (CIBERONC, CB16/12/00233), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain.
  • Departamento de Medicina, Universidad de Salamanca, 37007 Salamanca, Spain.
  • Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, 39008 Santander, Spain.

ORCID-Profile: Andrea Díaz-Tejedor, Mauro Lorenzo-Mohamed, Laura San-Segundo, Luis A Corchete, María-Victoria Mateos, Enrique M Ocio, Mercedes Garayoa, Teresa Paíno

Förderung

  • Mundipharma Research Limited; Purdue Pharma LP
  • Instituto de Salud Carlos III co-funded by European Union (ERDF, "A way to make Europe")
  • Instituto de Salud Carlos III co-funded by the European Union
  • Fundación Científica Asociación Española Contra el Cáncer
  • Fundación Ramón Areces
  • Consejería de Educación, Junta de Castilla y León and European Social Fund+
  • Ministerio de Ciencia, Innovación y Universidades
  • Instituto de Salud Carlos III

Zitieren

APA

Díaz-Tejedor, A., Rodríguez-Ubreva, J., Ciudad, L., Lorenzo-Mohamed, M., González-Rodríguez, M., Castellanos, B., Sotolongo-Ravelo, J., San-Segundo, L., Corchete, L. A., González-Méndez, L., Martín-Sánchez, M., Mateos, M. V., Ocio, E. M., Garayoa, M., & Paíno, T. (2024). Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands. International Journal of Molecular Sciences, 25(9), 4718. https://doi.org/10.3390/ijms25094718

Vancouver

Díaz-Tejedor A, Rodríguez-Ubreva J, Ciudad L, Lorenzo-Mohamed M, González-Rodríguez M, Castellanos B, et al. Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands. International Journal of Molecular Sciences. 2024;25(9):4718. doi:10.3390/ijms25094718

BibTeX
@article{DazTejedor2024,
  author = {Díaz-Tejedor, Andrea and Rodríguez-Ubreva, Javier and Ciudad, Laura and Lorenzo-Mohamed, Mauro and González-Rodríguez, Marta and Castellanos, Bárbara and Sotolongo-Ravelo, Janet and San-Segundo, Laura and Corchete, Luis A and González-Méndez, Lorena and Martín-Sánchez, Montserrat and Mateos, María-Victoria and Ocio, Enrique M and Garayoa, Mercedes and Paíno, Teresa},
  title = {Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {9},
  pages = {4718},
  doi = {10.3390/ijms25094718}
}
Kostenlos starten →